Figure 3From: A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients Waterfall plot of maximum reduction in tumour burden from baseline by dose level (135 mg/m 2 (white fill), 270 mg/m 2 (vertical lines), 540 mg/m 2 (diagonal lines), 675 mg/m 2 (horizonal lines) and 900 mg/m 2 (black fill)).Back to article page